Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
There are studies that are bound to succeed, and those that are likely to fail. A failed trial is nothing to be proud of – and in this case, it was a gamble against overwhelming odds. We feel the Gilead marketing department was pushing their luck big time with this Continue reading Obeldesivir Fails in Yet Another Study
As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1] There is a shortage of new antifungals for invasive disease. Small improvements in PK will hardly move the field forward or excite investors to engage. Our current Continue reading The Antifungal Landscape – 2
Some newer azoles are still in development, but most only target candidiasis. Many years ago we saw development of nikkomycin (Nik Z), a drug mainly for coccidioidomycosis (Valley Fever). It has no appreciable activity against candida or aspergillus. Then there is ibrexafungerp, a promising new agent against C. albicans and Continue reading The Antifungal Landscape – 1